CAMDEN, N.J. (Legal Newsline) — A woman alleges she developed a severe reaction to an eyelash- enhancing product that was deceptively sold as cosmetics when it contained the same active ingredients as a prescription drug.
Brenda Nixon, individually and on behalf of all others similarly situated, filed a complaint Nov. 16 in the U.S. District Court for the District of New Jersey against Grande Cosmetics LLC, alleging violation of consumer protection acts, fraud and other claims.
Nixon alleges in her class action that after using the defendant's GrandelLASH-MD enhancing product, she developed a severe reaction including swelling, pain, impaired eyelids and blurred vision. She claims that the defendant's beauty products "GrandeLASH-MD Lash Enhancing Serum," "GrandeBROW Brown Enhancing Serum" and "GrandeHAIR Enhancement Serum" are deceptively sold as cosmetics when they actually contain isopropyl cloprostenate (ICP) which contains the same active ingredient in prescription drugs for eyelash growth.
Nixon further claims Grande sells its enhancement serums without a prescription and with no warning of the serious side effects. She alleges in her suit that she and other consumers purchase the products without knowing they were "new, unapproved drugs" that can have serious side effects. Nixon further alleges Grande negligently used misleading, deceptive and fraudulent actions to sell its product.
Nixon and the class seek monetary relief, interest, trial by jury and all other just relief. They are represented by Ruben Honik and David Stanoch of Honik Law LLC in Philadelphia.
U.S. District Court for the District of New Jersey case number 1:22-CV-06639-RMB-MJS